Format

Send to:

Choose Destination
See comment in PubMed Commons below
Transpl Infect Dis. 2013 Feb;15(1):E28-32. doi: 10.1111/tid.12045. Epub 2012 Dec 26.

DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient.

Author information

  • 1Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195-6175, USA.

Abstract

Parainfluenza virus (PIV) may cause life-threatening pneumonia in lung transplant patients and there are no proven effective therapies. We report the use of inhaled DAS181, a novel sialidase fusion protein, to treat severe PIV type 3 pneumonia in a lung transplant patient. Treatment was well tolerated and associated with improvement in oxygenation and symptoms, along with rapid clearance of PIV. DAS181 should be systematically evaluated for treatment of PIV infection in transplant recipients.

© 2012 John Wiley & Sons A/S.

PMID:
23279859
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk